Topical tranexamic acid as an adjunct to pericervical tourniquet in reducing blood loss during abdominal myomectomy at Federal Teaching Hospital, Ido-Ekiti: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202505742818730

Enrollment

Registered

2025-05-09

Start date

2025-02-17

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraoperative haemorrhage during abdominal myomectomy

Interventions

Tranexamic acid Group A

Sterile water for injection Group B

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Eligible patients with symptomatic uterine fibroid size > 14 weeks scheduled for abdominal myomectomy.

Exclusion criteria

Exclusion criteria: 1. History of previous myomectomy or abdominopelvic surgeries. 2. Patients with fibroid size < 14 weeks. 3. History of hormone-therapy before the surgery. 4. Patients with chronic medical disorders such as hypertension, diabetes mellitus, cardiac, pulmonary, hepatic, renal or thromboembolic disease. 5. Patients with recognized allergy to TXA. 6. Pregnant women. 7. Patients with history of malignancy.

Design outcomes

Primary

Measure	Time frame
Primary outcome will be an estimation of intraoperative blood loss (ml) during abdominal myomectomy	—

Secondary

Measure	Time frame
1. Comparing the preoperative and postoperative PCV difference;, 2. The need for blood transfusion;3. Operative time;4. The period of hospitalization	—

Countries

Nigeria

Contacts

Public ContactEmmanuel Adewara

Consultant

waramide@yahoo.com+2348033184738

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026